CTIC - CTI BioPharma Corp.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.89
+0.01 (+0.26%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.88
Open3.88
Bid3.76 x 1000
Ask4.16 x 1500
Day's Range3.82 - 3.90
52 Week Range2.45 - 4.52
Volume69,054
Avg. Volume427,222
Market Cap225.546M
Beta-0.23
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • What Should You Know About CTI BioPharma Corp’s (NASDAQ:CTIC) Earnings Trajectory?
    Simply Wall St.3 days ago

    What Should You Know About CTI BioPharma Corp’s (NASDAQ:CTIC) Earnings Trajectory?

    The latest earnings announcement CTI BioPharma Corp’s (NASDAQ:CTIC) released in December 2017 confirmed company earnings became less negative compared to the previous year’s level as a result of recent tailwindsRead More...

  • Associated Presslast month

    CTI BioPharma reports 4Q loss

    The Seattle-based company said it had a loss of 33 cents per share. Losses, adjusted for stock option expense, came to 30 cents per share. The biotechnology company posted revenue of $462,000 in the period. ...

  • CTI BioPharma Corp (NASDAQ:CTIC): What Does It Mean For Your Portfolio?
    Simply Wall St.last month

    CTI BioPharma Corp (NASDAQ:CTIC): What Does It Mean For Your Portfolio?

    If you are a shareholder in CTI BioPharma Corp’s (NASDAQ:CTIC), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • When Will CTI BioPharma Corp (NASDAQ:CTIC) Breakeven?
    Simply Wall St.2 months ago

    When Will CTI BioPharma Corp (NASDAQ:CTIC) Breakeven?

    CTI BioPharma Corp’s (NASDAQ:CTIC): CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally.Read More...

  • Who Owns CTI BioPharma Corp (NASDAQ:CTIC)?
    Simply Wall St.3 months ago

    Who Owns CTI BioPharma Corp (NASDAQ:CTIC)?

    I am going to take a deep dive into CTI BioPharma Corp’s (NASDAQ:CTIC) most recent ownership structure, not a frequent subject of discussion among individual investors. The impact of aRead More...

  • How Is Novartis’s Kymriah Positioned for 2018?
    Market Realist3 months ago

    How Is Novartis’s Kymriah Positioned for 2018?

    In January 2018, the U.S. FDA (Food and Drug Administration) accepted Novartis’s (NVS) supplemental biologics license application (or SBLA) for Kymriah suspension for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL) who are not candidates for autologous stem cell transplant (or ASCT). The U.S. FDA granted Novartis’s sBLA for priority review. Also, the European Medicines Agency (or EMA) granted accelerated assessment to the marketing authorization application (or MAA) for Novartis’s Kymriah for the treatment of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (or ALL) and also for adults with relapsed or refractory DLBCL who are not candidates for ASCT.

  • What Are Analysts Saying About CTI BioPharma Corp’s (NASDAQ:CTIC) Earnings Trend?
    Simply Wall St.3 months ago

    What Are Analysts Saying About CTI BioPharma Corp’s (NASDAQ:CTIC) Earnings Trend?

    In September 2017, CTI BioPharma Corp (NASDAQ:CTIC) released its most recent earnings announcement, which confirmed that losses became smaller relative to the prrior year’s level as a result of recentRead More...

  • Capital Cube4 months ago

    ETFs with exposure to CTI BioPharma Corp. : January 1, 2018

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017
    Capital Cube4 months ago

    CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017

    Categories: Yahoo FinanceGet free summary analysis CTI BioPharma Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of CTI BioPharma Corp. – Madrigal Pharmaceuticals, Inc., Celgene Corporation, Amgen Inc., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Limited Sponsored ADR, Incyte Corporation, Eli Lilly and Company, Baxter International ... Read more (Read more...)

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of CTIC earnings conference call or presentation 6-Nov-17 9:30pm GMT

    Q3 2017 CTi Biopharma Corp Earnings Call

  • Does CTI BioPharma Corp’s (NASDAQ:CTIC) Past Performance Indicate A Stronger Future?
    Simply Wall St.4 months ago

    Does CTI BioPharma Corp’s (NASDAQ:CTIC) Past Performance Indicate A Stronger Future?

    Improvement in profitability and outperformance against the industry can be important characteristics in a stock for some investors. Below, I will assess CTI BioPharma Corp’s (NASDAQ:CTIC) track record on aRead More...

  • Is CTI BioPharma Corp (CTIC) Undervalued?
    Simply Wall St.5 months ago

    Is CTI BioPharma Corp (CTIC) Undervalued?

    CTI BioPharma Corp (NASDAQ:CTIC), a biotechnology company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM in the over the last fewRead More...

  • Capital Cube5 months ago

    ETFs with exposure to CTI BioPharma Corp. : November 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Associated Press5 months ago

    CTI BioPharma reports 3Q loss

    The Seattle-based company said it had a loss of 28 cents per share. Losses, adjusted for stock option expense, came to 25 cents per share. The biotechnology company posted revenue of $1.7 million in the ...

  • Capital Cube7 months ago

    ETFs with exposure to CTI BioPharma Corp. : October 2, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
    Capital Cube7 months ago

    CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017

    Categories: Yahoo FinanceGet free summary analysis CTI BioPharma Corp. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 22.23 million, Net Earnings of USD 5.40 million. Gross margins widened from 96.40% to 98.80% compared to the same period last year, operating (EBITDA) margins now 33.57% from -256.17%. Change in operating ... Read more (Read more...)

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of CTIC earnings conference call or presentation 3-Aug-17 8:30pm GMT

    Q2 2017 CTi Biopharma Corp Earnings Call

  • Associated Press9 months ago

    CTI BioPharma posts 2Q profit

    The Seattle-based company said it had profit of 3 cents per share. Earnings, adjusted for stock option expense, came to 6 cents per share. The biotechnology company posted revenue of $22.2 million in the ...

  • Capital Cube10 months ago

    ETFs with exposure to CTI BioPharma Corp. : June 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Thomson Reuters StreetEvents11 months ago

    Edited Transcript of CTIC earnings conference call or presentation 3-May-17 8:30pm GMT

    Q1 2017 CTi Biopharma Corp Earnings Call

  • CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017
    Capital Cubelast year

    CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017

    Categories: Yahoo FinanceGet free summary analysis CTI BioPharma Corp. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of CTI BioPharma Corp. – Novartis AG Sponsored ADR, Eli Lilly and Company, Amgen Inc., Bristol-Myers Squibb Company, Baxter International Inc., Incyte Corporation and Celgene Corporation (NVS-US, LLY-US, AMGN-US, ... Read more (Read more...)

  • Associated Presslast year

    CTI BioPharma reports 1Q loss

    On a per-share basis, the Seattle-based company said it had a loss of 71 cents. Losses, adjusted for stock option expense, came to 65 cents per share. The biotechnology company posted revenue of $754,000 ...

  • Capital Cubelast year

    ETFs with exposure to CTI BioPharma Corp. : April 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)